Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Anavex Life Sciences Corp. (OTC: AVXL).

Full DD Report for AVXL

Recent News from (OTC: AVXL)

Wired News - Anavex Life Sciences To Commence Phase-2 Study of ANAVEX(R)2-73 in Parkinson's Disease Dementia
Stock Monitor: Aeterna Zentaris Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 19, 2018 / Active-Investors.com has just released a free research report on Anavex Life Sciences Corp. (NASDAQ: AVXL ) ("Anavex"). If you want access to this report all you need to do is sign up n...
Source: ACCESSWIRE IA
Date: April, 19 2018 07:20
Premarket Losers as of 9:05 am (4/17/2018)
LADR -9% . More news on: Ladder Capital Corp, Bellicum Pharmaceuticals, Anavex Life Sciences Corp., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: April, 17 2018 09:10
Anavex readies mid-stage study of lead candidate in PDD; shares ahead 2% premarket
Anavex Life Sciences (NASDAQ: AVXL ) is up  2%  premarket on average volume in response to its announcement that it plans to initiate a Phase 2 clinical trial evaluating lead candidate ANAVEX 2-73 in patients with Parkinson's Disease Dementia (PDD). The study should launch in H2....
Source: SeekingAlpha
Date: April, 17 2018 08:28
Anavex Life Sciences to Initiate Phase 2 Study of ANAVEX®2-73 in Parkinson's Disease Dementia and Provides Clinical Study Update for ANAVEX®2-73 in Rett Syndrome
NEW YORK, April 17, 2018 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental dise...
Source: GlobeNewswire
Date: April, 17 2018 07:07
Oryzon Genomics on go with mid-stage study of Alzheimer's candidate ORY-2001
Madrid, Spain-based Oryzon Genomics announces that it has received regulatory sign-off for a Phase 2a clinical trial assessing ORY-2001 in patients with mild-to-moderate Alzheimer's disease (AD). More news on: Alzheon, Denali Therapeutics, Inc., Wave Life Sciences, Healthcare stocks news...
Source: SeekingAlpha
Date: April, 04 2018 11:14
Report: Exploring Fundamental Drivers Behind Anavex Life Sciences, Methode Electronics, Wesco Aircraft, Monotype Imaging, Tejon Ranch, and Pareteum - New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, March 29, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Anavex Life Sciences Corp. (NASDAQ:AVXL), Methode Electronics, Inc. (NYS...
Source: GlobeNewswire
Date: March, 29 2018 07:55
Anavex 2-73 And The Stabilization Of Alzheimer's Disease
Despite the limitations of Anavex's ( AVXL ) current trial, there are a number of reasons to remain optimistic about the potential of Anavex 2-73 to treat Alzheimer's disease and to be confident about the company's long-term future. At high concentrations, Anavex 2-73 appears to lead to some...
Source: SeekingAlpha
Date: March, 12 2018 08:50
Anavex Life Sciences to Present at the 30th Annual ROTH Conference
NEW YORK, March 09, 2018 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental dise...
Source: GlobeNewswire
Date: March, 09 2018 07:00
Premarket analyst action - healthcare
Cowen, Barclays and ROTH all host healthcare conferences next week. More news on: Anavex Life Sciences Corp., Owens & Minor Inc., Verastem, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: March, 08 2018 08:26
Anavex Life Sciences to Present New Preclinical Data at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics (ASENT)
ANAVEX®2-73 Extends Survival and Reduces Seizures in an Orphan Disease Model NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) --  Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing d...
Source: GlobeNewswire
Date: March, 07 2018 07:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-04-212.282.282.302.22226,030
2018-04-202.282.282.302.22226,030
2018-04-192.162.262.272.14333,479
2018-04-182.132.172.182.08268,451
2018-04-172.062.092.181.851,244,109

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

Short Analysis provided by Squeeze Report.


About Anavex Life Sciences Corp. (OTC: AVXL)

Logo for Anavex Life Sciences Corp. (OTC: AVXL)

Anavex is a pharmaceutical company engaged in the development of drug candidates.

 

Contact Information

 

 

Current Management

  • Christopher Missling / President, CEO, CFO
  • Christine Payne / IR
  • Sandra Boenisch / Principal Acct. Officer
  • Christopher Missling / Chairman
  • Elliot Favus /
  • Bernd Metzner /
  • Athanasios Skarpelos /
  • Steffen Thomas /

Current Share Structure

  • Market Cap: $119,012,014 - 03/20/2018
  • Authorized: 100,000,000 - 10/07/2015
  • Issue and Outstanding: 44,573,788 - 02/07/2018

 


Recent Filings from (OTC: AVXL)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 20 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 08 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: February, 07 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: December, 11 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: October, 06 2017
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: September, 07 2017
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: August, 11 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 07 2017

 

 


Daily Technical Chart for (OTC: AVXL)

Daily Technical Chart for (OTC: AVXL)


Stay tuned for daily updates and more on (OTC: AVXL)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: AVXL)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

Monsta Trader
@MonstaTrader

 

 


Disclaimer: Monsta Trader publishes reports providing information on selected companies. Monsta Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. Monsta Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AVXL is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Monsta Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. Monsta Trader does not own any shares of AVXL and does not buy, sell, or trade any shares of AVXL. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2016 by Monsta Trader. All rights reserved. Our Full Disclaimer: http://monstatrader.com/disclaimer/

 

 

Release this Report to Investors

Via Email

Via Text

Important

If you would like to schedule the release please Contact Us and we will assist you otherwise we will release this report to investors 15 minutes after payment is received to allow the most current information to be updated before the report is sent. Interested in reaching more investors? Contact Us